Clinical Trials Browser

Phase 1/2 × Neoplasms × rociletinib × Clear all

NCT01526928 2020-08-04

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 1/2 Terminated

612 enrolled 34 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence